MaRS Discovery District, Toronto, ON; December 1, 2021 – Proteocyte AI is pleased to announce its formal engagement with Medlior, a health outcomes research provider based in Calgary, Alberta.
Proteocyte will rely on Medlior’s team of diverse subject matter experts to bring scientific expertise, experience and a sound methodology to allow the company to make even more informed business and regulatory decisions as they work toward commercialization of Straticyte™, its innovative oral cancer risk stratification solution.
On the heels of its recent $1.1 million fundraising round, the Proteocyte team has been working with Medlior to craft a detailed strategic plan around the research needed to bring Straticyte™ closer to its commercial release.
“Medlior brings a wealth of practical, real-world experience to this project and their insights will be invaluable to our organization in the coming months,” according to Dr. Anthony Morlandt, CEO of Proteocyte AI. “Their initial mandate is to complete an independent review of our unpublished data sets, a highly necessary step in our evolution as a company that will be offering personalized medicine with the aid of data-driven artificial intelligence.”
“We are excited to be supporting Proteocyte in assessing the value of Straticyte™,” says Suzanne McMullen , Principal at Medlior. “Oral cancers are associated with a large burden of illness, and Straticyte™ offers huge potential for earlier diagnosis and improved outcomes for patients. We love collaborations where our team’s support and experience has the opportunity to create meaningful downstream impacts to improve patient lives.”
Proteocyte AI is a personalized medical diagnostic company located in MaRS Centre, Toronto, ON. Proteocyte’s product helps tackle the uncertainty surrounding oral cancer care, one of the most aggressive human cancers. The company’s oral dysplasia predictive test, Straticyte, was developed from a panel of 811 protein biomarkers, leveraging over 10 years of R&D, and is positioned to disrupt oral dysplasia and cancer care worldwide.